Meeting
2022 ASCO Annual Meeting
TIRA study: A phase III, multicenter, randomized controlled study of toripalimab plus radical chemoradiotherapy with or without concurrent cisplatin in patients with high-risk locoregionally advanced nasopharyngeal carcinoma.
Authors
Cheng Xu
Sun Yat-sen University Cancer Center, Guangzhou, China
Cheng Xu , Jun Ma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04907370
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6101)
DOI
10.1200/JCO.2022.40.16_suppl.TPS6101
Abstract #
TPS6101
Poster Bd #
90b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde
Poster
2019 ASCO Annual Meeting
A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
First Author: Guru Sonpavde
Poster
2018 ASCO Annual Meeting
Comparison between lobaplatin and cisplatin plus 5-fluorouracil combined with intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized phase III clinical trial.
First Author: Kuiyuan Liu
Poster
2017 ASCO Annual Meeting
Phase III randomized trial of image-guided bone marrow-sparing intensity modulated radiation therapy (IG-BMS-IMRT) for locoregionally advanced cervical cancer: The INTERTECC-3 trial.
First Author: Loren K. Mell